Physician profile
Isaac Raijman
NPI 1689679557
$565,176.56
in general payments reported to CMS, 2019-2025
45 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297K · 2020: $38K · 2021: $32K · 2022: $52K · 2023: $48K · 2024: $24K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Food and Beverage: $10K · Travel and Lodging: $9,088 · Consulting Fee: $8,863 · Royalty Or License: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,925.00 |
| Food and Beverage | $10,132.67 |
| Travel and Lodging | $9,087.70 |
| Consulting Fee | $8,862.50 |
| Royalty Or License | $1,609.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $286,960.42 | 2019-2025 | Spyglass, Spyglass, Autotome Rx 49 |
| Conmed Corporation | $256,753.23 | 2019-2024 | Stone Balloons, Conmed Generators |
| Medtronic, INC. | $6,076.16 | 2022-2025 | Beacon, Gi Genius, Sharkcore |
| Abbvie INC. | $2,992.52 | 2019-2025 | |
| Gi Supply, INC. | $2,516.50 | 2019 | |
| Ambu INC. | $2,228.69 | 2020-2023 | |
| Micro-Tech Endoscopy USA, INC. | $1,249.47 | 2019-2025 | Lesionhunter, Eus Fna Needle, Eyemax |
| Takeda Pharmaceuticals U.S.A., INC. | $897.67 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $877.07 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $651.74 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $495.56 | 2021-2024 | Zeposia |
| Pfizer INC. | $469.90 | 2021-2025 | |
| Olympus Corporation of The Americas | $437.92 | 2019-2025 | Single Use Aspiration Needle Na-U200h |
| Olympus America INC. | $310.15 | 2019-2024 | Single Use Aspiration Needle Na-U200h, Hanarostent Esophagus Tts(Ccc) |
| Apollo Endosurgery US INC | $264.87 | 2021-2022 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Raijman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.